An elite team of young, transpacific scientists out of Harvard and MIT starts plowing next-gen cell therapy tech field
This isn’t the complete story about the latest biotech upstart to raise its head in the cell therapy field. It’s not even half the story. But it is an intriguing glimpse — based largely on the people who are involved.
Even before the first CAR-Ts hit the market, just about everyone who was anyone in the field had set their sights on the next leg of the clinical journey. Impressive as they were in the first pivotal trials, cell therapies bristled with limitations related to the kind of cells they relied on, their easily exhausted state that blunted durability and a lean selection that would benefit from more powerful dosing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
